PCSK9 Drug Dramatically Cuts Apheresis in FH

ACC Conference Reporter

ESC Congress 2016 | ROME — The PCSK9 inhibitor alirocumab (Praluent) reduced the frequency of apheresis treatments for familial hypercholesterolemia (FH) patients dramatically and allowed most patients to drop them entirely, the ESCAPE trial showed. Read More >>>

Keywords: ESC Congress


< Back to Listings